Steve Skikos

Steven Skikos, a founding partner of Skikos, Crawford, Skikos & Joseph LLP, has been a trial attorney since 1990. Skikos has tried multiple pharmaceutical and medical device cases, tried numerous employment law cases in state and federal court on behalf of plaintiffs and defendants, prosecuted and tried criminal cases while clerking at the United States Attorney’s Office in San Francisco, and tried personal injury cases. Since 1996, Skikos has focused on complex pharmaceutical drug and medical device litigation. He has been court-appointed lead and/or liaison counsel for California Judicial Counsel Coordinated Proceedings (JCCP) and/or for the federal Multidistrict Litigation (MDL) in more than a dozen cases. Skikos has been a lead negotiator responsible for settling more than $4 billion in cases for tens of thousands of plaintiffs and has served as strategic leader in several more national litigations.

• Plaintiff’s Co-Liaison Counsel and member of the Plaintiff’s Executive Committee appointed by the Honorable Dan A. Polster in the National Prescription Opiatecase before the U.S. District Court for the Northern District of Ohio. [In re: National Prescription Opiate Litigation, MDL No. 2804, U.S. District Court, Northern District of Ohio]
• Plaintiff’s Co-Liaison Counsel and member of the Plaintiff’s Executive Committee appointment by the Honorable Curtis E.A. Karnow in the California North Bay Fire Cases, JCCP No. 4955, San Francisco Superior Court.
• Co-Lead Counsel appointed by the Honorable David Katz resulting in a multibillion-dollar settlement for almost 10,000 patients suffering a revision surgery and other consequences from the recalled DePuy ASR hip implant. [In re: DePuy Orthopedics Inc. ASR Hip Implant Products Liability Litigation, MDL No. 2197, U.S. District Court, Northern District of Ohio]
• Co-Lead Counsel and Court Appointed Co-Liaison for the California Reglan/MetoclopramideLitigation Judicial Council Coordination Proceedings (JCCP No. 4631), San Francisco Superior Court. The case resulted in a $250 million nationwide settlement resolving approximately 5,000 cases located in 18 different venues and involving three coordinated jurisdictions with 16 pharmaceutical brand and generic manufacturer defendant groups.
• The firm’s recent work on behalf of patients taking generic pharmaceutical products has resulted in Teva v. Superior Courtand amicus brief for the United States Supreme Court in the Fosamax/Alendronate Sodium Drug Cases, JCCP No. 464